ZMI Pharma

Executive Summary

ZMI Pharma is a San Diego-based specialty pharmaceutical company dedicated to developing and commercializing generic drugs, with a current focus on emergency rescue medications. Its sole product, ZIMHI, is a high-dose intramuscular naloxone injection (5 mg/0.5 mL) approved for the emergency treatment of opioid overdose. As a private, single-product company, ZMI Pharma operates in a rapidly growing market driven by the ongoing opioid crisis and increasing public health initiatives to expand naloxone access. The company's narrow product focus and lack of disclosed funding or partnerships present both an opportunity for specialized market leadership and a risk due to dependence on a single asset. Competition includes other naloxone formulations, such as Narcan nasal spray, which has gained over-the-counter status. ZMI Pharma's ability to differentiate via high-dose intramuscular delivery may appeal to institutional buyers like emergency responders and government agencies.

Upcoming Catalysts (preview)

• Q2 2027Potential Over-the-Counter (OTC) Switch for ZIMHI30% success
• Q4 2026Securing a Distribution or Government Supply Contract40% success
• TBDAnnouncement of a New Pipeline Product20% success